"Cancer"

Ovarian cancer symptoms in pre-clinical invasive epithelial ovarian cancer: An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Ovarian cancer symptoms in pre- clinical invasive epithelial ovarian cancer An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) | NIHR Journals Library opens in a new Technology Assessment Ovarian cancer symptoms in pre- clinical invasive epithelial ovarian cancer An exploratory analysis nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) 1. Journals Library 2. Health Technology Assessment 3. Ovarian cancer symptoms in pre- clinical invasive epithelial ovarian cancer An exploratory analysis nested within the UK Collaborative Trial of Ovarian

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer Clinical guideline Published: 25 June 2013 Last updated: 14 November 2023 www.nice.org.uk/guidance/cg164 © NICE 2023. All and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Familial breast cancer: classification, care and managing breast cancer and related risks inpeople with a family history of breast cancer (CG164)© NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Page 2

Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over Technology appraisal guidance Published: 12 February 2025 www.nice.org.uk/guidance/ta1038 © NICE 2025. All rights reserved to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Selpercatinib for advanced thyroid cancer with RET alterations after treatment

Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over Selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer drug in people 12 years and over Technology appraisal guidance Published: 12 February 2025 www.nice.org.uk/guidance/ta1039 © NICE 2025. All rights reserved. Subject unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Selpercatinib for advanced thyroid cancer with RET alterations untreated

Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial Ovarian cancer population screening and mortality after long- term follow- up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial | NIHR Journals Library opens in a new window Assessment Ovarian cancer population screening and mortality after long- term follow- up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial 1. Journals Library 2. Health Technology Assessment 3. Ovarian cancer population screening and mortality after long- term follow- up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised

Serial endometrial thickness and risk of non-endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening Serial endometrial thickness and risk of non- endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening | NIHR Journals Library opens in a new window Skip to main content Journals thickness and risk of non- endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening 1. Journals Library 2. Health Technology Assessment 3. Serial endometrial thickness and risk of non- endometrial hormone-dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening * Type: External Article Our publication formats

Ovarian cancer symptoms, routes to diagnosis and survival: population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Ovarian cancer symptoms, routes to diagnosis and survival population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) | NIHR Journals Library opens in a new window Skip Assessment Ovarian cancer symptoms, routes to diagnosis and survival population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) 1. Journals Library 2. Health Technology Assessment 3. Ovarian cancer symptoms, routes to diagnosis and survival population cohort study in the 'no screen' arm of the UK Collaborative Trial of Ovarian Cancer Screening

Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials: an ovarian cancer exemplar Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials an ovarian cancer exemplar | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search * Permissions * Production process * Outputs and external publications * Editorial policies * Latest updates * For Reviewers For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Health Technology Assessment Completeness and accuracy of national cancer and death registration for outcome

Advanced breast cancer: diagnosis and treatment Advanced breast cancer: diagnosis and treatment Clinical guideline Published: 23 February 2009 Last updated: 19 February 2025 www.nice.org.uk/guidance/cg81 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Advanced breast cancer: diagnosis and treatment (CG81)© NICE 2025. All rights reserved. Subject to Notice of rights ( 2 of17 Contents

Early and locally advanced breast cancer: diagnosis and management Early and locally advanced breast cancer: diagnosis and management NICE guideline Published: 18 July 2018 www.nice.org.uk/guidance/ng101 © NICE 2023. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 5 April 2023Your responsibility The recommendations health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Early and locally advanced breast cancer

Suspected cancer: recognition and referral Suspected cancer: recognition and referral NICE guideline Published: 23 June 2015 www.nice.org.uk/guidance/ng12 © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 15 December 2021Your responsibility Your responsibility The recommendations in this guideline represent and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Suspected cancer: recognition and referral (NG12)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 15 December 2021Page 2of 90Contents Contents Overview

Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer Interventional procedures guidance Published: 2 April 2024 www.nice.org.uk/guidance/ipg784 Your responsibility This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising for non-melanoma skin cancer. 1.2 This procedure should only be done as part of a formal research study and a research ethics committee needs to have approved its use. 1.3 More research is needed on: • details of patient selection • tumour histology • the site and size of the tumour • the dose and number of treatments • the treatment margin around the tumour • remission status • patient-reported outcome

Ovarian cancer: identifying and managing familial and genetic risk Ovarian cancer: identifying and managing familial and genetic risk NICE guideline Published: 21 March 2024 www.nice.org.uk/guidance/ng241 © NICE 2024. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights).Your responsibility The recommendations in this guideline represent inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Ovarian cancer: identifying and managing familial

Lung cancer: diagnosis and management Lung cancer: diagnosis and management NICE guideline Published: 28 March 2019 www.nice.org.uk/guidance/ng122 © NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 11 August 2022Your responsibility The recommendations in this guideline represent the view of NICE, arrived system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Lung cancer: diagnosis and management (NG122)© NICE 2022. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights). Last updated 11 August 2022Page 2of 48Contents Overview

Cancer Care Ontario Thyroid Cancer Guideline: An Endorsement of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer Guideline Endorsement 5-13 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) Cancer Care Ontario Thyroid Cancer Guideline: An Endorsement of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer J. Yoo, C. Agbassi, H. Lochnan, D. Morrison, A. M. Sawka, J. Brierley, and the Head and Neck Disease Site Group Thyroid Cancer Subcommittee Report Date: June 5, 2023 This publication is an endorsement of the 2015 American Thyroid Association (ATA) Management Guidelines

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer Technology appraisal guidance Published: 19 February 2025 www.nice.org.uk/guidance/ta1042 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility The recommendations in this guidance is recommended as an option for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults, only if: • it has been treated before and • the company provides selpercatinib according to the commercial arrangement. 1.2 This recommendation is not intended to affect treatment with selpercatinib that was started in the NHS before this guidance

Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer Technology appraisal guidance Published: 19 February 2025 www.nice.org.uk/guidance/ta1041 © NICE 2025. All rights reserved. Subject to Notice of rights ( responsibility of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Durvalumab with etoposide and either carboplatin or cisplatin for untreated extensive-stage small-cell lung cancer (TA1041)© NICE 2025

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection Technology appraisal guidance Published: 26 February 2025 www.nice.org.uk/guidance/ta1043 © NICE 2025. All rights reserved. Subject to Notice of rights Osimertinib is recommended, within its marketing authorisation, as an option for the adjuvant treatment of stage 1b to 3a non-small-cell lung cancer (NSCLC) after complete tumour resection. It is for adults whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or EGFR exon 21 (L858R) substitution mutations. It is only recommended if: • osimertinib is stopped at 3 years, or earlier

Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal) Technology appraisal guidance Published: 12 March 2025 www.nice.org.uk/guidance/ta1047 © NICE 2025 cancer whenplatinum-doublet chemotherapy is unsuitable (terminated appraisal) (TA1047)© NICE 2025. All rights reserved. Subject to Notice of rights ( 2of 3 Advice NICE is unable to make a recommendation about the use in the NHS of atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable in adults. This is because Roche Products has

Cancer in English prisons: a mixed-methods study of diagnosis, treatment, care costs and patient and staff experiences Cancer in English prisons: a mixed-methods study of diagnosis, treatment, care costs and patient and staff experiences | NIHR Journals Library opens in a new window Skip to main content Journals Library Search Journals Library Menu Journals Library Search Journals Library * Production process * Outputs and external publications * Editorial policies * Latest updates * For Reviewers For Reviewers * For reviewers * Become a reviewer * About Journals Library About Journals Library * About us * Support for researchers * Policies * FAQs * Contact us Close menu Health and Social Care Delivery Research Cancer in English prisons: a mixed-methods study of diagnosis, treatment, care